Imophoron Announces Publication of Scientific Paper Highlighting the Importance of Thermostability in Global Vaccine Distribution
BRISTOL, UK – 25 July 2024 – Imophoron, a biopharmaceutical company developing thermostable nanoparticle vaccines using its ADDomer™ platform, today announced the publication in Science Translational Medicine of a scientific viewpoint highlighting the direct link between vaccine temperature sensitivities and successful distribution of vaccines globally.
The paper, titled "Improving vaccine equity by increasing vaccine thermotolerance profiles”, reviews the unequal distribution of SARS-CoV-2 vaccines using novel vaccine technologies during the pandemic, highlighting a significant gap in the thermotolerance profiles of available vaccines that needs addressing to maximise the health impact of vaccination programmes globally. The authors propose aspirational targets for future vaccine development that cover both enhanced short term storage profiles, critical for achieving ‘last mile’ delivery, and longer term storage profiles that could reduce the costs associated with vaccine storage and delivery. The authors suggest that such targets represent a significant advancement in vaccine stability that could impact global health in both emergency and routine vaccination situations.
Richard Bungay, Chief Executive of Imophoron, commented: “This thought-provoking paper highlights the importance of thermostability in both managing the significant cost of vaccine distribution and ensuring equitable global access to vaccines. Imophoron is pleased to be at the forefront of developing nanoparticle vaccines with intrinsic thermostability, reflecting its ongoing commitment to advancing global health.”
The paper can be downloaded at Improving vaccine equity by increasing vaccine thermotolerance profiles.
For further information, please visit www.imophoron.com or contact:
Richard Bungay, Chief Executive Officer
About Imophoron
Imophoron was founded in 2017 and has developed a thermostable nanoparticle platform, ADDomer, a disruptive technology for the development of vaccines. The ADDomer platform is focused initially on the development of vaccines to combat present and future infectious diseases, and also has significant potential to treat diseases with high unmet needs such as oncology. The ADDomer platform is based on a self-assembling thermotolerant protein that permits rapid insertion of large numbers of epitopes in a single particle. Imophoron is building a pipeline of thermostable, nanoparticle ADDomer vaccines, including multivalent approaches, to address critical medical challenges that impact communities worldwide.